Evidence map›Paper›PMID 32528882›Full record

ArticleFrontiers in oncology2020

Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28.

Chaoxu Zhang, Yibo Fan, Xiaofang Che, Min Zhang, Zhi Li, Ce Li, Shuo Wang, Ti Wen, Kezuo Hou, Xinye Shao and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 6 pooled it
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 6 syntheses or guidelines pooled it, 67 citations in OpenAlex.

  1. Correlation between exosomal PD-L1 and prognosis in patients with cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Harnessing biomarkers to guide immunotherapy in esophageal cancer: toward precision oncology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Chaoxu ZhangDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Yibo FanDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Xiaofang CheDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Min ZhangDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Zhi LiDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Ce LiDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Shuo WangDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Ti WenDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Kezuo HouDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Xinye ShaoDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Yunpeng LiuDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Xiujuan QuDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
First Hospital of China Medical University · CNChina Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-PD-1 therapy has been approved for cancer treatment. However, the response rate is unsatisfactory. The expression of PD-L1 in tumor tissues is unreliable to predict the treatment response. Recent studies have suggested that exosomal PD-L1 not only exerts immunosuppressive effects but also plays a significant role in the development of tumor microenvironment. Thus, the present study aims to investigate exosomal PD-L1 in improving its predictive value and efficacy. A total of 44 patients of advanced tumors of several types, treated with anti-PD-1 therapy, were enrolled. Exosomes were collected and purified from plasma. The exosomal PD-L1 was detected with ELISA. The cytokines were measured with the MILLIPLEX magnetic bead assay. Compared to the responders, exosomal PD-L1 of the non-responders was significantly higher than that of the responders (

Indexed as

anti-PD-1 therapyCD28exosomal PD-L1immune checkpoint inhibitorresponse prediction

Identifiers

PMID32528882
PMCPMC7266952
OpenAlexW3030731299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.